Navigating the CMS 14-Day Rule in Biomarker TestingVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. David Rimm and Roy Herbst review the problems with the CMS “14-Day Rule” since some of the multigene panel biomarker tests require 21 days or longer to complete.
Drs. Geoffrey Oxnard and Lauren Ritterhouse consider the current landscape of reimbursement for molecular biomarker testing, the need to run FDA-approved tests, and the role of CMS and local Medicare providers in testing reimbursement.
Atheer Kaddis, SVP Sales/Business Development of Diplomat Specialty Pharmacy, describes in his opinion how specialty pharmacy can assist patients with polycythemia veraSupported through funding from Incyte